Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Department of Neurosurgery, Medical University of Graz, Auenbruggerplatz 29, 8036, Graz, Austria.
Clin Neuroradiol. 2024 Sep;34(3):663-673. doi: 10.1007/s00062-024-01407-1. Epub 2024 Apr 19.
Pre-surgical information about tumor consistency could facilitate neurosurgical planning. This study used multi-dynamic-multi-echo (MDME)-based relaxometry for the quantitative determination of pituitary tumor consistency, with the aim of predicting lesion resectability.
Seventy-two patients with suspected pituitary adenomas, who underwent preoperative 3 T MRI between January 2020 and January 2022, were included in this prospective study. Lesion-specific T1-/T2-relaxation times (T1R/T2R) and proton density (PD) metrics were determined. During surgery, data about tumor resectability were collected. A Receiver Operating Characteristic (ROC) curve analysis was performed to investigate the diagnostic performance (sensitivity/specificity) for discriminating between easy- and hard-to-remove by aspiration (eRAsp and hRAsp) lesions. A Mann-Whitney-U-test was done for group comparison.
A total of 65 participants (mean age, 54 years ± 15, 33 women) were enrolled in the quantitative analysis. Twenty-four lesions were classified as hRAsp, while 41 lesions were assessed as eRAsp. There were significant differences in T1R (hRAsp: 1221.0 ms ± 211.9; eRAsp: 1500.2 ms ± 496.4; p = 0.003) and T2R (hRAsp: 88.8 ms ± 14.5; eRAsp: 137.2 ms ± 166.6; p = 0.03) between both groups. The ROC analysis revealed an area under the curve of 0.72 (95% CI: 0.60-0.85) at p = 0.003 for T1R (cutoff value: 1248 ms; sensitivity/specificity: 78%/58%) and 0.66 (95% CI: 0.53-0.79) at p = 0.03 for T2R (cutoff value: 110 ms; sensitivity/specificity: 39%/96%).
MDME-based relaxometry enables a non-invasive, pre-surgical characterization of lesion consistency and, therefore, provides a modality with which to predict tumor resectability.
术前肿瘤硬度信息可有助于神经外科规划。本研究采用基于多动态多回波(MDME)的弛豫度定量测定垂体瘤硬度,旨在预测病变可切除性。
本前瞻性研究纳入了 2020 年 1 月至 2022 年 1 月期间在 3T 术前 MRI 检查中疑似垂体腺瘤的 72 例患者。测定病变特异性 T1-/T2-弛豫时间(T1R/T2R)和质子密度(PD)指标。术中收集肿瘤可切除性数据。采用受试者工作特征(ROC)曲线分析来评估用于区分易吸除(eRAsp)和难吸除(hRAsp)病变的诊断性能(灵敏度/特异性)。采用曼-惠特尼 U 检验进行组间比较。
共有 65 例患者(平均年龄 54 岁±15 岁,33 例女性)纳入定量分析。24 个病变被归类为 hRAsp,41 个病变被评估为 eRAsp。两组间 T1R(hRAsp:1221.0 ms±211.9;eRAsp:1500.2 ms±496.4;p=0.003)和 T2R(hRAsp:88.8 ms±14.5;eRAsp:137.2 ms±166.6;p=0.03)存在显著差异。ROC 分析显示 T1R 的曲线下面积为 0.72(95%CI:0.60-0.85),p=0.003(截断值:1248 ms;灵敏度/特异性:78%/58%),T2R 的曲线下面积为 0.66(95%CI:0.53-0.79),p=0.03(截断值:110 ms;灵敏度/特异性:39%/96%)。
MDME 弛豫度测定可实现病变硬度的非侵入性术前特征描述,因此提供了一种预测肿瘤可切除性的方法。